SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced plans to offer 5,000,000 shares of common stock in an underwritten public offering pursuant to an effective shelf registration statement. The Company intends to grant the underwriters an option to purchase an additional 750,000 shares of common stock to cover over-allotments.
Needham & Company, LLC is acting as sole lead bookrunning manager for the proposed offering. A.G. Edwards & Sons, Inc. is acting as a co-manager.
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering may be made only by means of a prospectus supplement and the accompanying prospectus.
A preliminary prospectus supplement and the accompanying base prospectus will be filed with the Securities and Exchange Commission and will be available on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, which meet the requirements of the Securities Act of 1933, as amended, can be obtained upon request in writing to Needham & Company, LLC, 445 Park Avenue, New York, New York 10022.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company’s leading product in development is Riquent(R), which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions. The Company’s common stock is traded on The NASDAQ Global Market under the symbol LJPC.
La Jolla Pharmaceutical Company
CONTACT: Andrew Wiseman, Ph.D., Sr. Director of Investor Relations of LaJolla Pharmaceutical Company, +1-858-646-6615, andrew.wiseman@ljpc.com; orMedia, Shellie M. Roth, President of Investor Relations Partners, Inc.,+1-973-535-8389, roth@irpartners.com, for La Jolla Pharmaceutical Company
